Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pen-administered low-dose dasiglucagon for prevention and treatment of hypoglycemia in type 1 diabetes
2020-005745-16Phase 2Completed
- Sponsor
- Steno Diabetes Center Copenhagen
- Start
- Feb 2021
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of dasiglucagon in diabetes mellitus type 1 (T1D) and hypoglycaemia (2 arms), sponsored by Steno Diabetes Center Copenhagen. Primary endpoint: Percentage of time in target glucose range. Started Feb 2021; status: completed.
02
Drugs
dasiglucagon
03
Conditions
diabetes mellitus type 1 (T1D)hypoglycaemia
Beyond the preview
Go deeper on 2020-005745-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005745-16.